PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy in the western world, has been historically treated with surgery followed by chemotherapy. Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most active new targeted therapies for the treatment of EOC. PARPis’ mechan...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2022
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/83332 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
- PARP Inhibitors in Ovarian Cancer
- Tumor Microenvironment of Epithelial Ovarian Cancer
- Preventive Strategies in Epithelial Ovarian Cancer
- Demographic and Clinical Characteristics of Mucinous Epithelial Ovarian Cancer, and Survival Following a Mucinous Epithelial Ovarian Cancer Diagnosis
- Central Nervous System Involvement from Epithelial Ovarian Cancer
- The Role of PARP Activation in Prostate Cancer